London: Insmead said Experimental drug proved to be very effective in treating a type of chronic lung disease alleviating respiratory symptoms Such as chronic cough in recent studies, boosting its shares doubled in premarket trading on Tuesday.

The drug candidate, brensocatib, is being developed to treat patients Non-cystic fibrosis bronchiectasisA Chronic lung disease Where the walls of the airways become widened due to inflammation and infection. bronchiectasis According to Insmed, the disease affects approximately 450,000 patients in the United States, and causes symptoms such as excessive mucus production, shortness of breath, and frequent respiratory infections.

The company said it plans to file a complaint. Marketing Applications For brensocatib U.S. Food and Drug Administration In fourth quarter early this year, and the drug is expected to be launched in mid-2025. (Reporting by Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri and Shinjini Ganguly)